Los Angeles Capital Management LLC Sells 42,195 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Los Angeles Capital Management LLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 30.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 94,822 shares of the biopharmaceutical company’s stock after selling 42,195 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.07% of Alnylam Pharmaceuticals worth $22,313,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALNY. Huntington National Bank boosted its stake in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC boosted its stake in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ALNY shares. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $303.83.

Alnylam Pharmaceuticals Trading Down 1.5 %

NASDAQ ALNY opened at $245.20 on Wednesday. The business’s 50-day moving average price is $254.21 and its two-hundred day moving average price is $262.72. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market capitalization of $31.74 billion, a PE ratio of -112.99 and a beta of 0.35. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,986 shares of company stock worth $20,397,849 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.